(CercleFinance.com) – AstraZeneca announces that Beyfortus (nirsevimab), developed with Sanofi, has been approved in China for the prevention of lower respiratory tract infection (LRTI) by respiratory syncytial virus (RSV) in new -borns and infants entering or during their first RSV season.
Beyfortus is expected to be available during the upcoming 2024-2025 RSV season.
‘As an innovative long-acting monoclonal antibody, Beyfortus can protect infants throughout the RSV season with a single dose. Its approval in China could potentially ease the disease burden on children and their families and ease the pressure on the medical system due to pediatric respiratory diseases,’ commented Professor Liu Hanmin, president of West China Second University Hospital, Sichuan University.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
